JO
CORT icon

John Overdeck’s Corcept Therapeutics CORT Stock Holding History

John Overdeck’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53M Sell
610,078
-335,806
-36% -$20.3M 0.04% 536
2026
Q1 		$38.1M Buy
945,884
+917,925
+3,283% +$34.3M 0.03% 613
2025
Q4 		$973K Sell
27,959
-14,167
-34% -$1.11M ﹤0.01% 2935
2025
Q3 		$3.5M Sell
42,126
-18,718
-31% -$1.35M 0.01% 1741
2025
Q2 		$4.47M Sell
60,844
-119,305
-66% -$8.65M 0.01% 1286
2025
Q1 		$20.6M Sell
180,149
-22,379
-11% -$1.36M 0.04% 479
2024
Q4 		$10.2M Sell
202,528
-153,522
-43% -$8.04M 0.02% 743
2024
Q3 		$16.5M Sell
356,050
-37,730
-10% -$1.34M 0.04% 563
2024
Q2 		$12.8M Sell
393,780
-424,695
-52% -$11.6M 0.03% 616
2024
Q1 		$20.6M Buy
818,475
+340,918
+71% +$8.05M 0.05% 434
2023
Q4 		$15.5M Buy
477,557
+222,292
+87% +$6.1M 0.04% 502
2023
Q3 		$6.95M Buy
255,265
+80,721
+46% +$2.34M 0.02% 744
2023
Q2 		$3.88M Buy
+174,544
New +$4.02M 0.01% 1047
2020
Q2 		– Sell
-10,554
Closed -$125K – 3016
2020
Q1 		$125K Buy
+10,554
New +$131K ﹤0.01% 2796
2019
Q2 		– Sell
-18,597
Closed -$218K – 3374
2019
Q1 		$218K Buy
+18,597
New +$231K ﹤0.01% 2776
2018
Q1 		– Sell
-133,732
Closed -$2.42M – 3194
2017
Q4 		$2.42M Sell
133,732
-233,167
-64% -$4.22M 0.01% 1338
2017
Q3 		$7.08M Buy
366,899
+189,573
+107% +$2.83M 0.03% 651
2017
Q2 		$2.09M Sell
177,326
-5,603
-3% -$60.9K 0.01% 1386
2017
Q1 		$2M Sell
182,929
-429,871
-70% -$3.78M 0.01% 1456
2016
Q4 		$4.45M Buy
612,800
+393,999
+180% +$3.09M 0.02% 911
2016
Q3 		$1.42M Buy
218,801
+26,069
+14% +$152K 0.01% 1716
2016
Q2 		$1.05M Buy
192,732
+49,474
+35% +$257K ﹤0.01% 1693
2016
Q1 		$670K Sell
143,258
-96,575
-40% -$376K ﹤0.01% 1855
2015
Q4 		$1.19M Buy
239,833
+24,636
+11% +$111K 0.01% 1389
2015
Q3 		$809K Buy
215,197
+53,558
+33% +$272K ﹤0.01% 1309
2015
Q2 		$971K Buy
+161,639
New +$991K ﹤0.01% 1671

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

John Overdeck's CORT Position: Q2 2026 in Review

John Overdeck reduced its Corcept Therapeutics (CORT) stake by 36% in Q2 2026, selling an estimated $20.3M and leaving 610,078 shares worth $53M. The position accounts for 0.04% of the portfolio, ranked #536.

John Overdeck first reported a position in CORT in Q2 2015 and has held it in 26 quarters since. 420 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • John Overdeck held 610,078 shares of Corcept Therapeutics worth $53M as of Q2 2026.
  • John Overdeck sold 335,806 Corcept Therapeutics shares in Q2 2026, an estimated $20.3M.
  • Corcept Therapeutics made up 0.04% of John Overdeck's portfolio in Q2 2026, its #536 holding.
  • John Overdeck first reported a position in Corcept Therapeutics in Q2 2015 and has held it in 26 quarters since.
  • 420 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.